Catalyst Wire Dossier Catalyst Wire Dossier

Ragweed sublingual immunotherapy tablet (SCH 39641)

ragweed pollen sublingual immunotherapy tablet · ALK-Abelló A/S
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ragweed sublingual immunotherapy tablet (SCH 39641), covering 2014-07-03 to 2014-07-03. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) [Phase 2, Phase 3]

See pricing